

**#4054** Store at -20C

## Phospho-Drosophila Akt (Ser505) Antibody



**Orders:** 877-616-CELL (2355)  
orders@cellsignal.com

**Support:** 877-678-TECH (8324)

**Web:** info@cellsignal.com  
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

**For Research Use Only. Not for Use in Diagnostic Procedures.**

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source:	UniProt ID:	Entrez-Gene Id:
WB	Dm	Endogenous	65	Rabbit	#Q8INB9	41957

### Product Usage Information

#### Application

Western Blotting

#### Dilution

1:1000

### Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

### Specificity / Sensitivity

Phospho Drosophila Akt (Ser505) Antibody detects endogenous levels of Akt only when phosphorylated at serine 505. It does not recognize drosophila Akt when phosphorylated at other sites, nor does it recognize related kinases such as PKC or p70 S6 Kinase.

### Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues around Ser505 of drosophila Akt. Antibodies are purified by protein A and peptide affinity chromatography.

### Background

Akt, also referred to as PKB or Rac, plays a critical role in controlling cell survival and apoptosis (1-3). This protein kinase is activated by insulin and various growth and survival factors to function in a wortmannin-sensitive pathway involving PI3 kinase (2,3). Akt is activated by phospholipid binding and activation loop phosphorylation at Thr308 by PDK1 (4) and by phosphorylation within the carboxy terminus at Ser473. The previously elusive PDK2 responsible for phosphorylation of Akt at Ser473 has been identified as mammalian target of rapamycin (mTOR) in a rapamycin-insensitive complex with rictor and Sin1 (5,6). Akt promotes cell survival by inhibiting apoptosis through phosphorylation and inactivation of several targets, including Bad (7), forkhead transcription factors (8), c-Raf (9), and caspase-9. PTEN phosphatase is a major negative regulator of the PI3K/Akt signaling pathway (10). LY294002 is a specific PI3 kinase inhibitor (11). Another essential Akt function is the regulation of glycogen synthesis through phosphorylation and inactivation of GSK-3 $\alpha$  and  $\beta$  (12,13). Akt may also play a role in insulin stimulation of glucose transport (12). In addition to its role in survival and glycogen synthesis, Akt is involved in cell cycle regulation by preventing GSK-3 $\beta$ -mediated phosphorylation and degradation of cyclin D1 (14) and by negatively regulating the cyclin-dependent kinase inhibitors p27 Kip1 (15) and p21 Waf1/Cip1 (16). Akt also plays a critical role in cell growth by directly phosphorylating mTOR in a rapamycin-sensitive complex containing raptor (17). More importantly, Akt phosphorylates and inactivates tuberlin (TSC2), an inhibitor of mTOR within the mTOR-raptor complex (18,19).

Drosophila Akt (D-Akt) regulates multiple biological processes such as cell survival (20) and cell growth (21). Major sites of phosphorylation include Ser505 and Thr342. These activation sites are homologous to mammalian Ser473 and Thr308 respectively. Identified downstream targets of D-Akt include Trh (Ser665) (22) and Tsc2 (23). Like Akt, D-Akt functions in a wortmannin-sensitive pathway involving PI3 kinase (24).

### Background References

1. Franke, T.F. et al. (1997) *Cell* 88, 435-7.
2. Burgering, B.M. and Coffey, P.J. (1995) *Nature* 376, 599-602.
3. Franke, T.F. et al. (1995) *Cell* 81, 727-36.
4. Alessi, D.R. et al. (1996) *EMBO J* 15, 6541-51.
5. Sarbassov, D.D. et al. (2005) *Science* 307, 1098-101.
6. Jacinto, E. et al. (2006) *Cell* 127, 125-37.
7. Cardone, M.H. et al. (1998) *Science* 282, 1318-21.
8. Brunet, A. et al. (1999) *Cell* 96, 857-68.
9. Zimmermann, S. and Moelling, K. (1999) *Science* 286, 1741-4.
10. Cantley, L.C. and Neel, B.G. (1999) *Proc Natl Acad Sci USA* 96, 4240-5.
11. Vlahos, C.J. et al. (1994) *J Biol Chem* 269, 5241-8.
12. Hajdich, E. et al. (2001) *FEBS Lett* 492, 199-203.
13. Cross, D.A. et al. (1995) *Nature* 378, 785-9.
14. Diehl, J.A. et al. (1998) *Genes Dev* 12, 3499-511.
15. Gesbert, F. et al. (2000) *J Biol Chem* 275, 39223-30.

16. Zhou, B.P. et al. (2001) *Nat Cell Biol* 3, 245-52.
17. Navé, B.T. et al. (1999) *Biochem J* 344 Pt 2, 427-31.
18. Inoki, K. et al. (2002) *Nat Cell Biol* 4, 648-57.
19. Manning, B.D. et al. (2002) *Mol Cell* 10, 151-62.
20. Staveley, B. E. et al. (1998) *Curr Biol* 8(10) , 599-602.
21. Scanga, S. E. et al. (2000) *Oncogene* 19, 3971-3977.
22. Jin, J. et al. (2001) *Dev Cell* 1(6) , 726-728.
23. Potter, C. J. et al. (2002) *Nature Cell Biology* 4, 658-665.
24. Linassier, C. et al. (1997) *Biochem. J.* 321, 849-856.

**Species Reactivity**

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

**Western Blot Buffer**

**IMPORTANT:** For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

**Applications Key**

**WB:** Western Blotting

**Cross-Reactivity Key**

**H:** human **M:** mouse **R:** rat **Hm:** hamster **Mk:** monkey **Vir:** virus **Mi:** mink **C:** chicken **Dm:** D. melanogaster  
**X:** Xenopus **Z:** zebrafish **B:** bovine **Dg:** dog **Pg:** pig **Sc:** S. cerevisiae **Ce:** C. elegans **Hr:** horse  
**GP:** Guinea Pig **Rab:** rabbit **All:** all species expected

**Trademarks and Patents**

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.  
 All other trademarks are the property of their respective owners. Visit [cellsignal.com/trademarks](http://cellsignal.com/trademarks) for more information.

**Limited Uses**

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.